Inventisbio Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Inventisbio Shanghai Ltd. (to 2021)
0
Ending by 2030
Aug 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Heterocyclic compounds, preparation methods therefor, and methods of uses thereof (US 11,691,981) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Heterocyclic compounds, preparation methods and uses thereof (US 11,865,115) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Novel Salts of Selective Estrogen Receptor Degraders (US 11,903,931) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Inhibitor of indoleamine-2,3-dioxygenase (IDO) (US 11,969,425) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Selective estrogen receptor degraders and uses thereof (US 10,647,724) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,809,580 | Carboxylic acid compound, method for preparation thereof, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,856,239 | Carboxylic acid compound, method for preparation thereof, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,179,784 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,498,921 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,647,724 | Selective estrogen receptor degraders and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,014,936 | Selective estrogen receptor degraders and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,187,736 | Selective estrogen receptor degraders and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,980,807 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) In force · From the USPTO record | In force | From the USPTO record | |
| US 11,969,425 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) In force · From the USPTO record | In force | From the USPTO record | |
| US 11,685,720 | Salt Forms of URAT-1 Inhibitors In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 30: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 3 abandoned · 4 no status recorded